Drugs / AIDSVAX®B/E
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02376582 | Sep 2014 → Jan 2016 | HIV infectious disease | EuroVacc Foundation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIDSVAX B/E | “The proposed vaccine trial will generate safety, tolerability and immunogenicity data of a vaccination regimen with simultaneous administration of a candidate HIV DNA vaccine...” NCT02376582 ↗1“The secondary objective of the trial is to evaluate the effect of S. mansoni infection on the immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX® B/E vaccine regimen.” NCT02376582 ↗ |
| Modality | Vaccine | “a gp120 protein vaccine (AIDSVAX®B/E)” NCT02376582 ↗ |
| Route | Intramuscular | “4mg DNA and 600 mcg protein formulated with Alum co-administration (IM)” NCT02376582 ↗ |